Clinical trial

ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy

NCT04372927

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2021-12-10

PhasePHASE2

Study timeline

Study start (actual)2021-12-10Date precision: day

Registry last updated2023-06-13

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Locally Advanced Lung Non-Small Cell Carcinomaunresolved

Stage III Lung Cancer AJCC v8unresolved

Stage IIIA Lung Cancer AJCC v8unresolved

Stage IIIB Lung Cancer AJCC v8unresolved

Stage IIIC Lung Cancer AJCC v8unresolved

Interventions

CisplatinDRUG · verified · RxNorm: cisplatin

DurvalumabBIOLOGICAL

EtoposideDRUG · verified · RxNorm: etoposide

Hypofractionated Radiation TherapyRADIATION

PemetrexedDRUG · verified · RxNorm: pemetrexed

Sponsors & collaborators

University of Washingtonlead sponsor

AstraZenecacollaborator

Mapped research locations

SeattleWashington, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04372927 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.